TLVX01 is a first-in-class ribonucleoprotein vaccine based on human telomerase specially reengineered for cancer immunotherapy




TLVX01 has been tested in preclinical models (monkeys and mice) and a multicentric clinical trial in dogs. It is highly efficient at inducing regression of even large aggressive chemoresistant tumors without adverse effects.









https://fr.wikipedia.org/wiki/Vaccin#/media/Fichier:Smallpox_vaccine.jpg